title: Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.
abstract: Despite increasing evidence that precision therapy targeted to the molecular drivers of a cancer has the potential to improve clinical outcomes, high-grade epithelial ovarian cancer (OC) patients are currently treated without consideration of molecular phenotype, and predictive biomarkers that could better inform treatment remain unknown. Delivery of precision therapy requires improved integration of laboratory-based models and cutting-edge clinical research, with pre-clinical models predicting patient subsets that will benefit from a particular targeted therapeutic. Patient-derived xenografts (PDXs) are renewable tumor models engrafted in mice, generated from fresh human tumors without prior in vitro exposure. PDX models allow an invaluable assessment of tumor evolution and adaptive response to therapy. PDX models have been applied to pre-clinical drug testing and biomarker identification in a number of cancers including ovarian, pancreatic, breast, and prostate cancers. These models have been shown to be biologically stable and accurately reflect the patient tumor with regards to histopathology, gene expression, genetic mutations, and therapeutic response. However, pre-clinical analyses of molecularly annotated PDX models derived from high-grade serous ovarian cancer (HG-SOC) remain limited. In vivo response to conventional and/or targeted therapeutics has only been described for very small numbers of individual HG-SOC PDX in conjunction with sparse molecular annotation and patient outcome data. Recently, two consecutive panels of epithelial OC PDX correlate in vivo platinum response with molecular aberrations and source patient clinical outcomes. These studies underpin the value of PDX models to better direct chemotherapy and predict response to targeted therapy. Tumor heterogeneity, before and following treatment, as well as the importance of multiple molecular aberrations per individual tumor underscore some of the important issues addressed in PDX models.
authors.affiliation: Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital and The Royal Women's Hospital , Melbourne, VIC , Australia.
authors.forename: Clare L
authors.initials: CL
authors.lastname: Scott
authors.affiliation: Division of Medical Oncology, Mayo Clinic , Rochester, MN , USA.
authors.forename: Marc A
authors.initials: MA
authors.lastname: Becker
authors.affiliation: Division of Medical Oncology, Mayo Clinic , Rochester, MN , USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Haluska
authors.affiliation: The Kinghorn Cancer Centre, St Vincent's Clinical School, Garvan Institute of Medical Research , Sydney, NSW , Australia.
authors.forename: Goli
authors.initials: G
authors.lastname: Samimi
keywords: clinical trials; ovarian cancer; patient-derived xenografts; pre-clinical models; targeted therapy